Using multifunctional peptide conjugated Au nanorods for monitoring β-amyloid aggregation and chemo-photothermal treatment of Alzheimer's disease

Theranostics

Volumn 7, Issue 12, 2017, Pages 2996-3006

  Li, Meng ^a,b   Guan, Yijia ^a,b   Zhao, Andong ^a,b   Ren, Jinsong ^a   Qu, Xiaogang ^a  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Alzheimer's Disease; Au nanorod; A detectors; A inhibitors; Photothermal treatment; Polyoxometalates

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA15 20; GOLD NANOROD; MERCAPTAMINE; METAL DERIVATIVE; POLYOXOMETALATE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; AMYLOID; GOLD; NANOTUBE; PEPTIDE;

ABSORPTION; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL PROTECTION; CELL VIABILITY; CEREBROSPINAL FLUID; CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; IRRADIATION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PHOTOTHERMAL THERAPY; PROTEIN AGGREGATION; PROTEIN STRUCTURE; RAT; SYNTHESIS; ANIMAL; CHEMISTRY; METABOLISM; PATHOLOGY; PROCEDURES; THERMOTHERAPY; TUMOR CELL LINE;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; CELL LINE, TUMOR; CEREBROSPINAL FLUID; DRUG THERAPY; GOLD; HYPERTHERMIA, INDUCED; MICE; NANOTUBES; PEPTIDES; RATS;

EID: 85025475440     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.18459     Document Type: Article

References (69)

1. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003; 4: 49-60.
2. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov. 2004; 3: 205-14.
3. Hamley IW. The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. Chem Rev. 2012; 112: 5147-92.
4. Scott LE, Orvig C. Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease. Chem Rev. 2009; 109: 4885-910.
5. Gaggelli E, Kozlowski H, Valensin D, Valensin G. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem Rev. 2006; 106: 1995-2044.
6. Ghiam Y, Kenjiro O, Mohammed I. Amyloid β-protein assembly as a therapeutic target of Alzheimer's disease. Curr Pharm Des. 2008; 14: 3231-46.
7. Taylor M, Moore S, Mayes J, et al. Development of a proteolytically stable retro-inverso peptide inhibitor of β-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. Biochemistry. 2010; 49: 3261-72.
8. Hyung SJ, DeToma AS, Brender JR, et al. Insights into antiamyloidogenic properties of the green tea extract (-)-epigallocatechin-3-gallate toward metal-associated amyloid-β species. Proc Natl Acad Sci USA. 2013; 110: 3743-8.
9. Yang W, Wong Y, Ng OT, et al. Inhibition of Beta-Amyloid Peptide Aggregation by Multifunctional Carbazole-Based Fluorophores. Angew Chem Int Ed. 2012; 51: 1804-10.
10. Takahashi T, Mihara H. Peptide and protein mimetics inhibiting amyloid β-peptide aggregation. Acc Chem Res. 2008; 41: 1309-18.
11. Frydman-Marom A, Rechter M, Shefler I, Bram Y, Shalev DE, Gazit E. Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies. Angew Chem Int Ed. 2009; 48: 1981-6.
12. Tjernberg LO, Naslund J, Lindqvist F, Johansson J, Karlstromi AR, Thyberg J. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem. 1996; 271: 8545-8.
13. Liu L, Xu K, Wang H, et al. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat Nanotechnol. 2009; 4: 457-63.
14. Pan H, Soman NR, Schlesinger PH, Lanza GM, Wickline SA. Cytolytic peptide nanoparticles ('NanoBees') for cancer therapy. Nanomed Nanobiotechnol. 2011; 3: 318-27.
15. Li M, Xu C, Wu L, Ren J, Wang E, Qu X. Self-Assembled Peptide-Polyoxometalate Hybrid Nanospheres: Two in One Enhances Targeted Inhibition of Amyloid β-Peptide Aggregation Associated with Alzheimer's Disease. Small. 2013; 9: 3455-61.
16. Geng J, Li M, Wu L, Chen C, Qu X. Mesoporous Silica Nanoparticle-based H2O2 Responsive Controlled-Release System Used for Alzheimer's Disease Treatment. Adv Healthcare Mater. 2012; 1: 332-6.
17. Yang X, Liu X, Liu Z, Pu F, Ren J, Qu X. Near-Infrared Light-Triggered, Targeted Drug Delivery to Cancer Cells by Aptamer Gated Nanovehicles. Adv Mater. 2012; 24: 2890-5.
18. Li M, Shi P, Xu C, Ren J, Qu X. Cerium oxide caged metal chelator: anti-aggregation and anti-oxidation integrated H2O2-responsive controlled drug release for potential Alzheimer's disease treatment. Chem Sci. 2013; 4: 2536-42.
19. Feng X, Lv F, Liu L, Yang Q, Wang S, Bazan GC. A highly emissive conjugated polyelectrolyte vector for gene delivery and transfection. Adv Mater. 2012; 24: 5428-32.
20. Wiley DT, Webster P, Gale A, Davis ME. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci USA. 2013; 110: 8662-7.
21. Ren J, Shen S, Wang D, et al. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials. 2012; 33: 3324-33.
22. Nie G, Hah HJ, Kim G, et al. Hydrogel nanoparticles with covalently linked coomassie blue for brain tumor delineation visible to the surgeon. Small. 2012; 8: 884-91.
23. Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release. 2012; 161: 264-73.
24. Dilnawaz F, Singh A, Mewar S, Sharma U, Jagannathan NR, Sahoo SK. The transport of non-surfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model. Biomaterials. 2012; 33: 2936-51.
25. Ni W, Kou X, Yang Z, Wang J. Tailoring longitudinal surface plasmon wavelengths, scattering and absorption cross sections of gold nanorods. ACS Nano. 2008; 2: 677-86.
26. Eghtedari M, Oraevsky A, Copland JA, Kotov NA, Conjusteau A, Motamedi M. High sensitivity of in vivo detection of gold nanorods using a laser optoacoustic imaging system. Nano Lett. 2007; 7: 1914-8.
27. Chen CC, Lin YP, Wang CW, et al. DNA-gold nanorod conjugates for remote control of localized gene expression by near infrared irradiation. J Am Chem Soc. 2006; 128: 3709-15.
28. Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc. 2006; 128: 2115-20.
29. Huang J, Jackson KS, Murphy CJ. Polyelectrolyte wrapping layers control rates of photothermal molecular release from gold nanorods. Nano Lett. 2012; 12: 2982-7.
30. Kuo TR, Hovhannisyan VA, Chao YC, et al. Multiple release kinetics of targeted drug from gold nanorod embedded polyelectrolyte conjugates induced by near-infrared laser irradiation. J Am Chem Soc. 2010; 132: 14163-71.
31. Kogan MJ, Bastus NG, Amigo R, et al. Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano Lett. 2006; 6: 110-5.
32. Adura C, Guerrero S, Salas E, et al. Stable conjugates of peptides with gold nanorods for biomedical applications with reduced effects on cell viability. ACS Appl Mater Interfaces. 2013; 5: 4076-85.
33. Li M, Yang X, Ren J, Qu K, Qu X. Using Graphene Oxide High Near-Infrared Absorbance for Photothermal Treatment of Alzheimer's Disease. Adv Mater. 2012; 24: 1722-8.
34. Xiao Q, Zheng X, Bu W, et al. A Core/Satellite Multifunctional Nanotheranostic for in Vivo Imaging and Tumor Eradication by Radiation/Photothermal Synergistic Therapy. J Am Chem Soc. 2013; 135: 13041-8.
35. Yu C, Irudayaraj J. Multiplex biosensor using gold nanorods. Anal Chem. 2007; 79: 572-9.
36. Caswell KK, Wilson JN, Bunz UHF, Murphy CJ. Preferential end-to-end assembly of gold nanorods by biotin-streptavidin connectors. J Am Chem Soc. 2003; 125: 13914-5.
37. Park HS, Agarwal A, Kotov NA, Lavrentovich OD. Controllable side-by-side and end-to-end assembly of Au nanorods by lyotropic chromonic materials. Langmuir. 2008; 24: 13833-7.
38. Singh AK, Senapati D, Wang S, et al. Gold nanorod based selective identification of Escherichia coli bacteria using two-photon Rayleigh scattering spectroscopy. ACS Nano. 2009; 3: 1906-12.
39. Kida T. Synthesis of gold nanosheets at a liquid/liquid interface using an amphiphilic polyoxometallate/surfactant hybrid photocatalyst. Langmuir. 2008; 24: 7648-50.
40. Kang Z, Wang E, Jiang M, Lian S. Synthesis and characterization of polyoxometalate nanowires based on a novel microemulsion process. Nanotechnology. 2004; 15: 55-8.
41. Carraro M, Sartorel A, Scorrano G, et al. Chiral Strandberg-Type Molybdates [(RPO3)2Mo5O15]2- as Molecular Gelators: Self-Assembled Fibrillar Nanostructures with Enhanced Optical Activity. Angew Chem Int Ed. 2008; 47: 7275-9.
42. Liu S, Kurth DG, Bredenkötter B, Volkmer D. The Structure of Self-Assembled Multilayers with Polyoxometalate Nanoclusters. J Am Chem Soc. 2002; 124: 12279-87.
43. Nisar A, Zhuang J, Wang X. Cluster-based self-assembly: Reversible formation of polyoxometalate nanocones and nanotubes. Chem Mater. 2009; 21: 3745-51.
44. Zhang J, Song YF, Cronin L, Liu T. Self-Assembly of Organic-Inorganic Hybrid Amphiphilic Surfactants with Large Polyoxometalates as Polar Head Groups. J Am Chem Soc. 2008; 130: 14408-9.
45. Li H, Sun H, Qi W, Xu M, Wu L. Onionlike Hybrid Assemblies Based on Surfactant-Encapsulated Polyoxometalates. Angew Chem Int Ed. 2007; 46: 1300-3.
46. Ritchie C, Cooper GJ, Song YF, et al. Spontaneous assembly and real-time growth of micrometre-scale tubular structures from polyoxometalate-based inorganic solids. Nat Chem. 2009; 1: 47-52.
47. Zhang C, Bu W, Ni D, et al. A Polyoxometalate Cluster Paradigm with Self-Adaptive Electronic Structure for Acidity/Reducibility-Specific Photothermal Conversion. J Am Chem Soc. 2016; 138: 8156-64.
48. Shaw CP, Middleton DA, Volk M, Lévy R. Amyloid-derived peptide forms self-assembled monolayers on gold nanoparticle with a curvature-dependent β-sheet structure. ACS Nano. 2012; 6: 1416-26.
49. Geng J, Li M, Ren J, Wang E, Qu X. Polyoxometalates as inhibitors of the aggregation of amyloid β peptides associated with Alzheimer's disease. Angew Chem Int Ed. 2011; 50: 4184-8.
50. Schlamadinger DE, Kats DI, Kim JE. Quenching of tryptophan fluorescence in unfolded cytochrome c: A biophysics experiment for physical chemistry students. J Chem Educ. 2010; 87: 961-4.
51. Puchalski MM, Morra MJ, von Wandruszka R. Assessment of inner filter effect corrections in fluorimetry. Fresenius J Anal Chem. 1991; 340: 341-4.
52. Barten DM, Guss VL, Corsa JA, et al. Dynamics of β-amyloid reductions in brain, cerebrospinal fluid, and plasma of β-amyloid precursor protein transgenic mice treated with a ?-secretase inhibitor. J Pharmacol Exp Ther. 2005; 312: 635-43.
53. Murphy CJ, Gole AM, Stone JW, et al. Gold nanoparticles in biology: beyond toxicity to cellular imaging. Acc Chem Res. 2008; 41: 1721-30.
54. Qiu Y, Liu Y, Wang L, et al. Surface chemistry and aspect ratio mediated cellular uptake of Au nanorods. Biomaterials. 2010; 31: 7606-19.
55. LeVine III H. Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci. 1993; 2: 404-10.
56. Yu H, Li M, Liu G, et al. Metallosupramolecular complex targeting an a/β discordant stretch of amyloid β peptide. Chem Sci. 2012; 3: 3145-53.
57. Geng J, Li M, Wu L, Ren J, Qu X. Liberation of copper from amyloid plaques: making a risk factor useful for Alzheimer's disease treatment. J Med Chem. 2012; 55: 9146-55.
58. Wijaya A, Schaffer SB, Pallares IG, Hamad-Schifferli K. Selective release of multiple DNA oligonucleotides from gold nanorods. ACS Nano. 2009; 3: 80-6.
59. Halim A, Brinkmalm G, Rüetschi U, et al. Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid β-peptides in human cerebrospinal fluid. Proc Natl Acad Sci USA. 2011; 108: 11848-53.
60. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010; 6: 131-44.
61. Santa-María I, Pérez M, Hernández F, Avila J, Moreno FJ. Characteristics of the binding of thioflavin S to tau paired helical filaments. J Alzheimers Dis. 2006; 9: 279-85.
62. Boshuizen RS, Langeveld JP, Salmona M, Williams A, Meloen RH, Langedijk JP. An in vitro screening assay based on synthetic prion protein peptides for identification of fibril-interfering compounds. Anal Biochem. 2004; 333: 372-80.
63. Urbanc B, Cruz L, Le R, et al. Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc Natl Acad Sci USA. 2002; 99: 13990-5.
64. Hu X, Crick SL, Bu G, Frieden C, Pappu RV, Lee JM. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci USA. 2009; 106: 20324-9.
65. Peters I, Igbavboa U, Schütt T, et al. The interaction of beta-amyloid protein with cellular membranes stimulates its own production. Biochim Biophys Acta. 2009; 1788: 964-72.
66. Wiessner C, Wiederhold KH, Tissot AC, et al. The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011; 31: 9323-31.
67. Tucker-Schwartz JM, Meyer TA, Patil CA, Duvall CL, Skala MC. In vivo photothermal optical coherence tomography of gold nanorod contrast agents. Biomed Opt Express. 2012; 3: 2881-95.
68. Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol. 2001; 19: 316-7.
69. Schwartz JA, Shetty AM, Price RE, et al. Feasibility study of particle-assisted laser ablation of brain tumors in orthotopic canine model. Cancer Res. 2009; 69: 1659-67.